PORTLAND, Ore., July 14, 2011 /PRNewswire/ — QuantRx®
Biomedical Corporation (OTCQB:QTXB), an emerging leader in the
development and commercialization of innovative diagnostic products
based on its patented technology platforms, is pleased to announce
that following the successful resolution and full settlement of all
matters related to the QN Joint Venture as disclosed in a Form 8-K
filed with the SEC on July 8, 2011, the Company is currently
implementing a go to market strategy for its market ready
over-the-counter (OTC) healthcare products.
Further, the Company plans to initiate a clinical study to
confirm an innovative, and potentially practice changing, approach
to fetal genomic diagnostics using its patented PadKit technology.
These clinical investigations will be done in collaboration with
GMSBIOTECH, with initial data anticipated to be generated prior to
year end.
Dr. Shalom Hirschman, Chairman and CEO, stated, “The company is
developing strategic plans to bring products to market as quickly
as possible. Our OTC pads for daily feminine hygiene and
intergluteal pads for the temporary relief of hemorrhoids will be
the focus of the initial commercialization effort.”
Further, Dr, William Fleming, Chief Scientific Officer, stated,
“We are committed to building shareholder value by capitalizing on
our innovative patented diagnostic technologies, particularly our
genomic-based diagnostic technology targeting the monitoring of
recurring cancers and serious fetal genomic disease and health
conditions.”
About QuantRx Biomedical
QuantRx Biomedical Corporation (OTCQB: QTXB) is focused on the
development and commercialization of innovative over-the-counter
and genomic products for advanced diagnosis of serious disease and
health conditions. With synergistic expertise in the discovery of
diagnostic platforms leveraging a vast portfolio of intellectual
property, QuantRx’s mission is to introduce products for use by
its
‘/>”/>
